Anti-CD3ε/anti-WT1/HLA-A*02 bispecific T-cell engager (Roche)

N/A

Report date: 2026/03/24 20:00:35

Base Information

Drug NameAnti-CD3ε/anti-WT1/HLA-A*02 bispecific T-cell engager (Roche)
Drug Alias NameTCR-like WT1 T-cell bispecific antibody (Roche)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT-cell surface glycoprotein CD3 epsilon chain modulatorsAnti-Wilms' Tumour 1HLA Class I Histocompatibility Antigen, A-2 alpha Chain modulators
TargetsT-cell surface glycoprotein CD3 epsilon chainWilms' Tumour 1HLA Class I Histocompatibility Antigen, A-2 alpha Chain
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRoche Pharmaceutical Research and Early Development
China Registration ClassN/A

Develop Information

Active CompaniesRoche Pharmaceutical Research and Early Development
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A